MX393913B - Prevención y tratamiento de palpitación/fibrilación atrial con depuradores de gamma-cetoaldehídos. - Google Patents

Prevención y tratamiento de palpitación/fibrilación atrial con depuradores de gamma-cetoaldehídos.

Info

Publication number
MX393913B
MX393913B MX2019000120A MX2019000120A MX393913B MX 393913 B MX393913 B MX 393913B MX 2019000120 A MX2019000120 A MX 2019000120A MX 2019000120 A MX2019000120 A MX 2019000120A MX 393913 B MX393913 B MX 393913B
Authority
MX
Mexico
Prior art keywords
gamma
fibrillation
prevention
treatment
ketoaldehyde
Prior art date
Application number
MX2019000120A
Other languages
English (en)
Spanish (es)
Other versions
MX2019000120A (es
Inventor
Katherine T Murray
Ii L Jackson Roberts
Venkataraman Amarnath
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of MX2019000120A publication Critical patent/MX2019000120A/es
Publication of MX393913B publication Critical patent/MX393913B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MX2019000120A 2016-07-07 2017-07-07 Prevención y tratamiento de palpitación/fibrilación atrial con depuradores de gamma-cetoaldehídos. MX393913B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359705P 2016-07-07 2016-07-07
PCT/US2017/041211 WO2018009875A1 (en) 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers

Publications (2)

Publication Number Publication Date
MX2019000120A MX2019000120A (es) 2019-04-01
MX393913B true MX393913B (es) 2025-03-24

Family

ID=60913210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000120A MX393913B (es) 2016-07-07 2017-07-07 Prevención y tratamiento de palpitación/fibrilación atrial con depuradores de gamma-cetoaldehídos.

Country Status (11)

Country Link
US (2) US20190247375A1 (cg-RX-API-DMAC10.html)
EP (1) EP3481505B1 (cg-RX-API-DMAC10.html)
JP (1) JP7179353B2 (cg-RX-API-DMAC10.html)
CN (1) CN110022936A (cg-RX-API-DMAC10.html)
AU (1) AU2017293950B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019000251A2 (cg-RX-API-DMAC10.html)
CA (1) CA3030149A1 (cg-RX-API-DMAC10.html)
ES (1) ES3040735T3 (cg-RX-API-DMAC10.html)
MX (1) MX393913B (cg-RX-API-DMAC10.html)
PL (1) PL3481505T3 (cg-RX-API-DMAC10.html)
WO (1) WO2018009875A1 (cg-RX-API-DMAC10.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620836B1 (en) * 1997-01-22 2003-09-16 Jay Patrick Antiarrhythmic and tranquilizer composition and treatment
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2007121588A1 (en) 2006-04-25 2007-11-01 Medicure International Inc. Treatment of atrial fibrillation
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
US10975033B2 (en) * 2011-07-12 2021-04-13 Vanderbilt University Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers

Also Published As

Publication number Publication date
AU2017293950B2 (en) 2023-06-15
CA3030149A1 (en) 2018-01-11
JP2019520389A (ja) 2019-07-18
BR112019000251A2 (pt) 2019-04-16
US20190247375A1 (en) 2019-08-15
US20240189291A1 (en) 2024-06-13
WO2018009875A1 (en) 2018-01-11
AU2017293950A1 (en) 2019-01-31
EP3481505A4 (en) 2020-02-26
ES3040735T3 (en) 2025-11-04
MX2019000120A (es) 2019-04-01
EP3481505A1 (en) 2019-05-15
JP7179353B2 (ja) 2022-11-29
EP3481505C0 (en) 2025-09-03
CN110022936A (zh) 2019-07-16
PL3481505T3 (pl) 2026-01-26
EP3481505B1 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
IL269354A (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
PL3448421T3 (pl) Sposoby i kompozycje do zapobiegania i leczenia zrostów chirurgicznych
EP3551186A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT, IMPROVEMENT AND PREVENTION OF H. PYLORI INFECTIONS
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EP3719032A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF HAIR LOSS
IL263697A (en) Compounds, compositions and methods for prevention and/or treatment of cancer
ES2856150T5 (en) Use of an inverse transcriptase inhibitor for the treatment and prevention of degenerative diseases
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PH12016501838A1 (en) Compounds and their methods of use
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
EP3677264A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF ATOPIC DERMATITIS
EP3503866A4 (en) COMPOSITIONS AND METHODS OF RESTORATION OF INTEGRITY AND EPIDERMAL FUNCTION AND TREATMENT OF DERMATOLOGICAL DISEASES
ZA201900984B (en) Methods and compositions for the treatment of warts
WO2016109002A3 (en) Methods and compositions for the treatment of radiation-related disorders
GB202001422D0 (en) Compositions and methods for preventing or treating nephrolithiasis
IL264977B1 (en) Methods and preparations for treating melanoma
WO2016046759A3 (en) Compositions and methods for treating friedreich's ataxia
EP3716967C0 (en) COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF ACUTE RADIATION SYNDROME
NZ755501A (en) Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
EP3582791A4 (en) HYDROGEN SULPHIDE AND / OR NITRITE IN THE TREATMENT AND PREVENTION OF ATRIAL FIBRILLATION